Stammdaten
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Unternehmen & Branche
| Name | Genprex, Inc. |
|---|---|
| Ticker | GNPX |
| CIK | 0001595248 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 1,5 Mio. USD |
| Beta | -0,67 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -16,228,953 | 10,159,011 | 7,961,876 | ||
| 2025-09-30 | 10-Q | -3,799,240 | 3,562,513 | 767,807 | ||
| 2025-06-30 | 10-Q | -4,674,901 | 3,827,524 | 1,391,196 | ||
| 2025-03-31 | 10-Q | -3,964,601 | 6,009,687 | 3,867,855 | ||
| 2024-12-31 | 10-K | 0 | -21,111,163 | 4,124,325 | 1,620,155 | |
| 2024-09-30 | 10-Q | -4,315,987 | 3,907,265 | 1,664,971 | ||
| 2024-06-30 | 10-Q | -6,495,846 | 6,604,810 | 4,345,549 | ||
| 2024-03-31 | 10-Q | -5,968,869 | 12,564,591 | 8,756,680 | ||
| 2023-12-31 | 10-K | 0 | -30,860,461 | 10,670,592 | 7,416,384 | |
| 2023-09-30 | 10-Q | -7,748,243 | 16,643,625 | 12,305,493 | ||
| 2023-06-30 | 10-Q | -7,980,192 | 15,911,119 | 12,050,874 | ||
| 2023-03-31 | 10-Q | -9,202,774 | 23,320,078 | 18,484,861 | ||
| 2022-12-31 | 10-K | 0 | -23,740,621 | 25,085,027 | 22,274,740 | |
| 2022-09-30 | 10-K | 0 | -6,142,562 | 29,945,826 | 27,488,515 | |
| 2022-09-30 | 10-Q | 0 | -6,142,562 | 29,945,826 | 27,488,514 | |
| 2022-06-30 | 10-Q | 0 | -5,764,643 | 34,565,123 | 32,411,285 | |
| 2022-06-30 | 10-K | 0 | -5,764,642 | 34,565,123 | 32,411,285 | |
| 2022-03-31 | 10-Q | 0 | -5,309,817 | 39,409,431 | 37,024,614 | |
| 2021-12-31 | 10-K | 0 | -20,664,969 | 42,862,286 | 41,276,991 | |
| 2021-09-30 | 10-Q | 0 | -3,437,865 | 46,327,172 | 45,165,279 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-04-14 | LONGNECKER BRENT M | Director | Open Market Sale | -8 | 1.23 | -9.84 | -88,9% | |
| 2026-04-14 | LONGNECKER BRENT M | Director | Open Market Sale | -10 | 1.23 | -12.30 | -111,1% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.